Matinas BioPharma Holdings (MTNB) Current Assets (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Current Assets data on file, last reported at $2.8 million in Q1 2026.

• Current Assets for Q1 2026 came in at $2.8 million, down 62.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (down 62.7% YoY), and the FY2025 annual result was $4.1 million, down 49.22% from the prior year.
• Current Assets declined to $2.8 million in Q1 2026 per MTNB's latest filing, from $4.1 million in the prior quarter.
• Over five years, Current Assets peaked at $45.1 million in Q1 2022 and troughed at $2.8 million in Q1 2026.
• A 5-year average of $18.8 million and a median of $15.3 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets slumped 63.52% in 2024, then retreated 26.65% in 2025.
• A 5-year view of Current Assets shows it stood at $34.5 million in 2022, then slumped by 54.99% to $15.5 million in 2023, then tumbled by 48.37% to $8.0 million in 2024, then plunged by 49.22% to $4.1 million in 2025, then slumped by 30.92% to $2.8 million in 2026.
• Business Quant data shows MTNB's Current Assets at $2.8 million in Q1 2026, $4.1 million in Q4 2025, and $5.7 million in Q3 2025.